Primary Fibromyalgia
7
0
0
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 42/100
28.6%
2 terminated out of 7 trials
71.4%
-15.1% vs benchmark
43%
3 trials in Phase 3/4
100%
5 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia
A Randomized Trial of Oral Iron Therapy in Fibromyalgia
12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients
BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)
Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia